ECSP077986A - Procedimiento para preparar inhibidores de renina - Google Patents

Procedimiento para preparar inhibidores de renina

Info

Publication number
ECSP077986A
ECSP077986A EC2007007986A ECSP077986A ECSP077986A EC SP077986 A ECSP077986 A EC SP077986A EC 2007007986 A EC2007007986 A EC 2007007986A EC SP077986 A ECSP077986 A EC SP077986A EC SP077986 A ECSP077986 A EC SP077986A
Authority
EC
Ecuador
Prior art keywords
renin inhibitors
procedure
compound
relates
novel
Prior art date
Application number
EC2007007986A
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Hans Hirt
Frank Schaefer
Stuart John Mickel
Michael Foulkes
Walter Prikoszovich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP077986A publication Critical patent/ECSP077986A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a un procedimiento novedoso, pasos de procedimiento novedosos e intermediarios novedosos útiles en la síntesis de compuestos farmacéuticamente activos, en especial inhibidores de renina, tales como alisciren. Entre otras cosas, la invención se refiere a un procedimiento para la fabricación de un compuesto de la fórmula III, en donde R, R1, R2, R3 y PG son como se definen en la especificación, o una sal del mismo, tal fabricación comprende (preferiblemente consiste de) hacer reaccionar un compuesto de la fórmula I,con un reactivo capaz de transformar hidroxi a X en donde X es, por ejemplo, un grupo saliente.
EC2007007986A 2005-06-08 2007-12-07 Procedimiento para preparar inhibidores de renina ECSP077986A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0511686.8A GB0511686D0 (en) 2005-06-08 2005-06-08 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP077986A true ECSP077986A (es) 2008-01-23

Family

ID=34835327

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007986A ECSP077986A (es) 2005-06-08 2007-12-07 Procedimiento para preparar inhibidores de renina

Country Status (24)

Country Link
US (2) US7767831B2 (es)
EP (2) EP2080754A3 (es)
JP (2) JP2008542415A (es)
KR (1) KR20080014011A (es)
CN (1) CN101193860B (es)
AR (1) AR054374A1 (es)
AU (1) AU2006256938B2 (es)
BR (1) BRPI0611919A2 (es)
CA (1) CA2608575A1 (es)
EC (1) ECSP077986A (es)
GB (1) GB0511686D0 (es)
GT (1) GT200600208A (es)
IL (1) IL187004A0 (es)
MA (1) MA29563B1 (es)
MX (1) MX2007015418A (es)
NO (1) NO20080080L (es)
NZ (2) NZ562889A (es)
PE (2) PE20091359A1 (es)
RU (1) RU2418785C2 (es)
SG (1) SG155209A1 (es)
TN (1) TNSN07465A1 (es)
TW (1) TW200716544A (es)
WO (1) WO2006131304A2 (es)
ZA (1) ZA200709076B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
EP2225200B1 (en) * 2007-12-24 2013-10-16 DSM IP Assets B.V. Convergent synthesis of renin inhibitors and intermediates useful therein
EP2189442B1 (en) 2008-11-20 2014-10-01 Krka Tovarna Zdravil, D.D., Novo Mesto Process and intermediates for the preparation of aliskiren
US8779198B2 (en) 2009-08-11 2014-07-15 Novartis Ag Ring opening of lactones and lactams
US8203005B2 (en) 2009-10-29 2012-06-19 Carbo Design Llc Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren
WO2011098258A1 (en) * 2010-02-10 2011-08-18 Ratiopharm Gmbh Salts of aliskiren
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
CN111423325A (zh) * 2020-04-26 2020-07-17 江苏凯迪恩医药科技有限公司 基于蒽醌类药物的双醋瑞因合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570108A (en) * 1982-07-06 1986-02-11 Stroede Aake Protection device for electrical incandescent lamps
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) * 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
CA2121898A1 (en) * 1994-04-21 1995-10-22 Stephen Hanessian Synthesis of prototypes for renin inhibitors
JP2005231999A (ja) * 2000-03-08 2005-09-02 Banyu Pharmaceut Co Ltd カルバペネム誘導体の製造方法
CN100482636C (zh) 2000-07-05 2009-04-29 斯皮德尔药品公司 取代的辛酰胺的制备方法
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
ATE342887T1 (de) * 2000-12-14 2006-11-15 Speedel Pharma Ag Verfahren zur herstellung von aryloctanoyl-amiden
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU2006256938A1 (en) 2006-12-14
EP2080754A3 (en) 2010-06-02
US20100274027A1 (en) 2010-10-28
ZA200709076B (en) 2008-10-29
US7767831B2 (en) 2010-08-03
GT200600208A (es) 2007-03-28
CN101193860B (zh) 2013-01-02
EP1896411A2 (en) 2008-03-12
TW200716544A (en) 2007-05-01
GB0511686D0 (en) 2005-07-13
IL187004A0 (en) 2008-02-09
SG155209A1 (en) 2009-09-30
MX2007015418A (es) 2008-02-21
KR20080014011A (ko) 2008-02-13
EP2080754A2 (en) 2009-07-22
MA29563B1 (fr) 2008-06-02
PE20070075A1 (es) 2007-03-16
JP2013028607A (ja) 2013-02-07
RU2007148226A (ru) 2009-07-20
CN101193860A (zh) 2008-06-04
US20080207921A1 (en) 2008-08-28
WO2006131304A3 (en) 2007-07-19
CA2608575A1 (en) 2006-12-14
BRPI0611919A2 (pt) 2010-10-05
NZ562889A (en) 2011-11-25
PE20091359A1 (es) 2009-10-13
AU2006256938B2 (en) 2009-12-17
NO20080080L (no) 2008-01-04
JP2008542415A (ja) 2008-11-27
AR054374A1 (es) 2007-06-20
WO2006131304A2 (en) 2006-12-14
NZ591010A (en) 2012-06-29
TNSN07465A1 (en) 2009-03-17
RU2418785C2 (ru) 2011-05-20

Similar Documents

Publication Publication Date Title
ECSP077986A (es) Procedimiento para preparar inhibidores de renina
ECSP088368A (es) Derivados de 3-alquil-5-(4-alquil-5-oxo-tetrahidrofuran-2-il)-pirrolidin-2-ona como intermediarios en la síntesis de inhibidores de renina
ECSP099708A (es) Nuevos métodos
MX2012001463A (es) Proceso para la fabricacion de compuestos.
AR054818A1 (es) Proceso para preparar rosuvastatina e intermediarios
AR047739A1 (es) Polimorfos cristalinos de un ligando receptor de cxc-quimiocina
PE20061422A1 (es) Tigeciclina y metodos para preparar 9-nitrominociclina
RU2010126906A (ru) Способ получения производного индолинона
WO2008155338A3 (en) Process for the synthesis of intermediates of renin inhibitors such as aliskiren
ECSP088525A (es) Proceso para la preparación de aminas
ECSP088319A (es) Síntesis de inhibidores de renina que involucra una reacción de cicloadición
AR049668A1 (es) Proceso quimico para preparar esteres de 4,4 - difluorometil - 3 - oxo - butanoico por reaccion entre una amida y un ester.
BRPI0507318A (pt) métodos para reduzir um composto, para a produção de calcipotriol ou monoidrato de calcipotriol, e de um composto, e de reação da mistura de compostos, composto, e, uso de um composto
TW200726752A (en) Process for the production of intermediates for the preparation of tricyclic benzimidazoles
ATE480530T1 (de) Herstellungsverfahren für optisch aktive verbindungen
MXPA04008926A (es) Inhibidores de entrada a moleculas pequenas.
PE20090824A1 (es) Proceso para la preparacion de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterociclicas
ATE532516T1 (de) Verfahren zur synthese von glyt-1-hemmern
AR060622A1 (es) Proceso para la preparcion del ester 2-[ 4-(4- fluoro-2 - metil-1h -indol-5- iloxi)-5-metil pirrolo [2,1-f] [ 1,2,4] triazin -6-iloxi] -1- metiletilico del acido [(1r),2s ] -2- aminopropinoico
BRPI0410642A (pt) processo para sintetizar intermediários de inibidor de betailactamase
TW200730524A (en) Process for making heteroaryl amine intermediate compounds
JP2012240959A (ja) 光学活性β−アミノチオールまたは光学活性β−アミノスルホン酸誘導体の合成法
AR042946A1 (es) Procedimiento para la fabricacion de alcaloides quinazolina
PE20090431A1 (es) Procesos para preparar carboxaldehido oxazina biciclico e inhibidores de beta lactamasa
CL2004001019A1 (es) Sal de adicion de acido 1,5-naftaleno disulfonico de [(7r,8r,9r)-2,3-dimetil-8-hidroxi-7-(2-metoxi-etoxi)9-fenil-7,8,9,10-tetrahidro-imidazo-[1,2-h][1,7]naftiridina]; procedimiento de preparacion de dicha sal de adicion; y uso de la sal como compuest